Harvard Bioscience Inc (HBIO) is a publicly traded Healthcare sector company. As of October 6, 2026, HBIO trades at $8.59 with a market cap of $38.69M and a P/E ratio of -5.69. HBIO moved +0.00% today. Year to date, HBIO is +31.31%; over the trailing twelve months it is +94.55%. Its 52-week range spans $2.81 to $14.30. Rallies surfaces HBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for HBIO, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $8.59 |
| Market Cap | $38.69M |
| P/E Ratio | -5.69 |
| EPS | $-1.50 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.30 |
| 52-Week Low | $2.81 |
| Volume | 8.71K |
| Avg Volume | 0 |
| Revenue (TTM) | $87.81M |
| Net Income | $-10.41M |
| Gross Margin | 58.16% |
HBIO analyst coverage data. Average price target: $0.00.